NEW YORK (Reuters Health) - A "placebo effect" can cause a diverse array of symptoms in children when undergoing food allergy testing, according to the results of a study published in the current ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LOUISVILLE, Ky. ...
73.5% of patients treated with PALFORZIA met the primary endpoint of tolerating the 600 mg single dose of peanut protein at 12 months compared with 6.3% of patients receiving placebo. No serious or ...
SAN ANTONIO -- Epicutaneous immunotherapy (EPIT) administered through an investigational skin patch over 12 months led to more responses -- with favorable safety -- compared with placebo in ...
LOUISVILLE, Kentucky — Compared with placebo, treatment with peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia) significantly improved the amount of peanut protein that could be tolerated by ...
TipRanks on MSN
Regeneron advances phase 3 antibody trial in birch pollen eye allergy: What investors should know
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study OverviewRegeneron Pharmaceuticals has launched a new ...
Please provide your email address to receive an email when new articles are posted on . A single dose of Regeneron’s REGN1908/1909 significantly prevented reductions in FEV1 compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback